Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
NCT ID: NCT06043011
Last Updated: 2026-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2950 participants
OBSERVATIONAL
2023-09-27
2033-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Primary Rituximab and Maintenance
NCT00140582
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
NCT00209209
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
NCT01865110
Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma
NCT05486013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It will identify common therapeutic sequences and changes in the treatment of the disease, and will analyse the impact of novel treatments on the outcome of patients in routine care. Unmet needs and areas with the potential for improvement in routine care are to be identified.
At inclusion, data in patient characteristics, comorbidities, clinical characteristics and previous treatments, if applicable, are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and clinical outcome are documented.
Health-realted quality of life in patients with hematological malignancies will be evaluated for up to one year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic Lymphocytic Leukemia (CLL)
Patients with CLL receiving systemic treatment (physician's choice)
Routine care as per site standard.
Physician's choice according to patient's needs.
Diffuse Large B-cell Lymphoma (DLBCL)
Patients with DLBCL receiving systemic treatment (physician's choice)
Routine care as per site standard.
Physician's choice according to patient's needs.
Follicular Lymphoma (FL)
Patients with FL receiving systemic treatment (physician's choice)
Routine care as per site standard.
Physician's choice according to patient's needs.
Mantle Cell Lymphoma (MCL)
Patients with MCL receiving systemic treatment (physician's choice)
Routine care as per site standard.
Physician's choice according to patient's needs.
Marginal Zone Lymphoma (MZL)
Patients with MZL receiving systemic treatment (physician's choice)
Routine care as per site standard.
Physician's choice according to patient's needs.
Waldenström's macroglobulinemia (WM)
Patients with WM receiving systemic treatment (physician's choice)
Routine care as per site standard.
Physician's choice according to patient's needs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Routine care as per site standard.
Physician's choice according to patient's needs.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of the respective NHL
* If patient is alive: signed written informed consent
* For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.
* For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
iOMEDICO AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rainer Claus, Prof. Dr.
Role: STUDY_CHAIR
Universitätsklinikum Augsburg, Germany
Tobias Dechow
Role: STUDY_CHAIR
Studienzentrum Onkologie Ravensburg, Germany
Paul Graf La Rosée, Prof. Dr.
Role: STUDY_CHAIR
Schwarzwald-Baar Klinikum, Germany
Jens Kisro, Dr.
Role: STUDY_CHAIR
Lübecker Onkologische Schwerpunktpraxis, Germany
Patrick Marschner, Dr.
Role: STUDY_CHAIR
Praxis für Interdisziplinäre Hämatologie und Onkologie, Freiburg, Germany
Ingo Tamm, PD Dr.
Role: STUDY_CHAIR
Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany
Robert Zeiser, Prof. Dr.
Role: STUDY_CHAIR
Universitätsklinikum Freiburg, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Praxis für Interdisziplinäre Hämatologie und Onkologie
Freiburg im Breisgau, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
iOM-080485
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.